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Abstract  
Background: Tubulointerstitial fibrosis represents the key underlying pathology of Chronic 
Kidney Disease (CKD), yet treatment options remain limited. In this study, we investigated 
the role of connexin43 (Cx43) hemichannel-mediated adenosine triphosphate (ATP) release 
in purinergic-mediated disassembly of adherens and tight junction complexes in early tubular 
injury.  
Methods: Human primary proximal tubule epithelial cells (hPTECs) and clonal tubular 
epithelial cells (HK2) were treated with Transforming Growth Factor Beta1 (TGFβ1) ± 
apyrase, or ATPγS for 48h. For inhibitor studies, cells were co-incubated with Cx43 mimetic 
Peptide 5, or purinergic receptor antagonists Suramin, A438079 or A804598. 
Immunoblotting, single-cell force spectroscopy and trans-epithelial electrical resistance 
assessed protein expression, cell-cell adhesion and paracellular permeability. 
Carboxyfluorescein uptake and biosensing measured hemichannel activity and real-time 
ATP release, whilst a heterozygous Cx43+/- mouse model with unilateral ureteral obstruction 
(UUO) assessed the role of Cx43 in vivo. 
Results: Immunohistochemistry of biopsy material from patients with diabetic nephropathy 
confirmed increased expression of purinergic receptor P2X7. TGFβ1 increased Cx43 
mediated hemichannel activity and ATP release in hPTECs and HK2 cells. The cytokine 
reduced maximum unbinding forces and reduced cell-cell adhesion, which translated to 
increased paracellular permeability. Changes were reversed when cells were co-incubated 
with either Peptide 5 or P2-purinoceptor inhibitors. Cx43+/- mice did not exhibit protein 
changes associated with early tubular injury in a UUO model of fibrosis.  
Conclusion: Data suggest that Cx43 mediated ATP release represents an initial trigger in 
early tubular injury via its actions on the adherens and tight junction complex. Since Cx43 is 
highly expressed in nephropathy, it represents a novel target for intervention of 
tubulointerstitial fibrosis in CKD.   
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Graphical Abstract. 
In proximal tubular epithelial cells (PTECs), tight junction proteins, including zona 
occuludens-1 (ZO-1), contribute to epithelial integrity, whilst the adherens junction 
protein epithelial (E)-cadherin (ECAD) maintains cell-cell coupling, facilitating 
connexin 43 (Cx43) gap junction-mediated intercellular communication (GJIC) and the 
direct transfer of small molecules and ions between cells. In disease, such as diabetic 
nephropathy, the pro-fibrotic cytokine transforming growth factor beta1 (TGF1) 
binds to its receptor and recruits SMAD2/3 signalling ahead of changes in gene 
transcription and up-regulation of Cx43-mediated hemichannels (HC). Uncoupled 
hemichannels permit the release of adenosine triphosphate (ATP) in to the 
extracellular space ([ATP]e), where ATP binds to the P2X7 purinoreceptor and 
activates the nucleotide-binding domain and leucine-rich repeat containing (NLR) 
protein-3 (NLRP3) inflammasome. Inflammation results in epithelial-to-mesenchymal 
transition (EMT), fibrosis and tubular injury.  A major consequence is further loss of 
ECAD and reduced stickiness between cells, which can be functionally measured as a 
decrease in the maximum unbinding force needed to uncouple two adherent cells 
(Fmax). Loss of ECAD feeds forward to further lessen cell-cell coupling exacerbating 
the switch from GJIC to HC-mediated release of ATP. Reduction in ZO-1 impedes tight 
junction effectiveness and decreases trans-epithelial resistance (TER), resulting in 
increased paracellular permeability. 
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Background 
 
Affecting 10% of the global population and increasing in prevalence annually, Chronic 
Kidney Disease (CKD) is a health crisis from which millions die in the absence of a definitive 
treatment.[1] Individuals are more in danger of CKD if they have any one or more of a 
number of risk factors including high blood pressure, smoking, established cardiovascular 
disease and obesity.[2] Characterized by persistent inflammation and fibrosis, 
tubulointerstitial injury of the proximal region is the key underlying pathology of CKD and 
develops in response to a number of morphological and phenotypic changes culminating in 
loss of epithelial stability and increased extracellular matrix deposition.[3-4] Despite our 
understanding of these changes, knowledge of the stimuli that initiate activation of resident 
primary tubular epithelial cells remains limited. 
In recent years, trans-membrane proteins called connexins have attracted considerable 
interest as a potential future target for treatment of multiple disease states,[5-8] including 
various forms of CKD.[9] Connexins assemble into hexameric structures called 
hemichannels, forming pores in the membrane which directly link the cytoplasm of adjacent 
cells through the formation of gap junctions.[10] In the absence of cell-cell adhesion, gap 
junctions fail to form and uncoupled hemichannels allow paracrine release of adenosine 
triphosphate (ATP) into the local extracellular environment. [11]  
In CKD, diabetic nephropathy accounts for approximately 50% of patients presenting with 
end-stage renal failure.[1] Hyperglycemia and downstream changes in connexin expression 
are critical in the development and progression of secondary micro-vascular complications, 
[12-15] with glucose decreasing gap junction conductance and disrupting cellular homeostasis 
in a variety of cell types.[16-19] Evidence that connexin expression is linked to renal damage in 
CKD,[9][11-12][20-24] suggests that they represent a viable therapeutic target for treatment of the 
disease. Recent studies have confirmed elevated levels of predominant isoform Cx43, in 
human and rodent models of early renal disease[20-21] whilst the Cx43+/- UUO mouse 
demonstrates reduced collagen deposition and macrophage infiltration.[24] Work within our 
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group confirmed increased expression of Cx43 in the tubular region of biopsy material 
isolated from patients with diabetic nephropathy,[11]. Despite increased expression, 
Transforming Growth Factor Beta, the main pro-fibrotic cytokine linked to tubular injury in 
both diabetic nephropathy and other forms of CKD,[25] reduced gap junction mediated 
intercellular communication (GJIC) and increased hemichannel mediated ATP release.[11][27] 
With elevated levels of nucleotides and altered connexin expression linked to inflammation 
and fibrosis in multiple tissue types,[28-31] it seems plausible that the loss of GJIC and the 
subsequent switch to Cx43 mediated hemichannel ATP release in the proximal tubule may 
be instrumental in facilitating tubular injury. 
Loss of E-cadherin (ECAD) mediated cell-cell adhesion is pivotal in initiating a series of 
phenotypic and morphological events that precede tubulointerstitial fibrosis,[27][32-33] with the 
disassembly of the adherens junction (AJ) and tight junction (TJ) complexes linked to loss of 
epithelial stability, inflammation, fibrosis and impaired renal function.[34-35] In the present 
study, we combine in vivo and in vitro models of CKD to investigate if targeting Cx43 
expression and hemichannel activity through genetic and pharmacological blockade, could 
negate loss of markers linked with tubular injury, ultimately improving function through 
diminished hemichannel activity, restoration of E-cadherin mediated cell-cell adhesion and 
reduced paracellular permeability. Using an array of techniques to assess both changes in 
expression (immunohistochemistry, immunoblotting) and changes in function (e.g. ATP 
biosensing, single-cell force spectroscopy and trans-epithelial resistance) we demonstrate 
that increased Cx43 expression and hemichannel mediated ATP release promotes 
disassembly of adherens and tight junction complexes in human primary proximal tubule 
epithelial cells and in the unilateral ureteral obstruction (UUO) mouse model of advanced 
fibrosis in which the initiating cause is tubulointerstitial inflammation.[24][36] Blockade of 
hemichannel mediated ATP release by the Cx43 mimetic Peptide 5, reduces disassembly of 
the adherens/tight junction complex and restores epithelial integrity. Importantly, these 
observations were paralleled in the Cx43+/- UUO model, where Cx43 expression is reduced 
by 50%. Up-regulated in renal tubules of people with diabetic nephropathy (DN) and linked 
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to multiple models of disease and fibrosis,[37-40] P2X7 appears instrumental in mediating 
these ATP driven effects. Together, our study indicates that aberrant Cx43-mediated ATP 
release may represent a future therapeutic target in preventing early tubular injury linked to 
tubulointerstitial fibrosis (TIF) in CKD.  
 
Methods 
Animal model 
Three-month-old SV129 Cx43+/- male mice and age-matched wild-type littermates (n=7) 
were generated. Unilateral ureteral obstruction surgery was performed as describe 
previously.[41] Non-obstructed kidneys were used as controls. Mice were handled in strict 
accordance with good animal practice, as defined by the relevant national animal welfare 
bodies of France, and all work was approved by the appropriate committee of the National 
Institute for Health and Medical Research (INSERM) and the Sorbonne Université (Paris, 
France). Animals were housed at constant temperature with ad libitum access to water and 
food. 
 
Biopsy staining 
Kidney biopsy slices were obtained from patients with biopsy-proven diabetic nephropathy 
(DN) (mean age 55; mean diabetes duration: 6.2yrs; mean HbA1C: 7.2%; mean serum 
creatinine: 464µmol/L; mean proteinuria: 5.80g/24h, n=10). Control renal tissue was 
obtained from 5 nephrectomy specimens treated for renal carcinoma (mean age 61; mean 
serum creatinine: 87.8µmol/L, n=6). As described previously,[42] paraffin-embedded renal 
sections (4μm) were de-paraffinized, rehydrated and subjected to microwave-based antigen 
retrieval in citric buffer solution (10mM), followed by quenching in 1% H2O2 and blocking in 
2% BSA solution. Sections were stained overnight with anti-P2Y2 (Santa-Cruz, 1:50), anti-
P2Y6 (Novus Biologicals, 1:250) or anti-P2X7 (Novus Biologicals, 1:200) antibodies and 
subsequently incubated with DAKO EnVision+ System-HRP antibodies (Dako, Carpinteria, 
CA). Rabbit IgG was incubated with both DN and control renal sections for isotype-matched 
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negative controls. DAB substrate was used for visualisation and sections were 
counterstained with hematoxylin. Quantitative analysis was measured by Image-Pro Plus 6.0 
and presented as a value of integrated optical density (IOD).  
 
Cell Culture and Treatment 
Human kidney (HK2) cells (passage 18-30) were maintained in DMEM/Hams F12 medium, 
supplemented with 10% FCS wt/vol, glutamine (2mmol/l) and EGF (5ng/ml), in a humidified 
atmosphere at 37°C with 5%CO2. Cells are proximal tubular epithelial cells, immortalized by 
the transduction of human papilloma virus 16 (HPV-16) E6/E7 genes and are mycoplasma-
free. For all treatments, cells were seeded in low-glucose DMEM/F12 (5mmol/L) for 48h, 
then serum-starved overnight prior to treatment with Transforming Growth Factor Beta-1 
(TGFβ1) (2-10ng/mL) or ATPS (1-100M) for 48h. For ATP experiments, cells were 
incubated with either TGFβ1 (10ng/mL) or ATPγS (100uM)  ATP-diphosphohydrolase 
apyrase (5Units/ml); Suramin (100µM), A438079 (50µM) or A804598 (50nM) for 48h. 
 
Primary human proximal tubule epithelial cells (hPTECs) were maintained in the basal 
medium obtained from the American Type Culture Collection (ATCC), supplemented with 
the renal epithelial cell growth kit (PCS-400-040) in a humidified atmosphere at 37°C with 
5% CO2. Cells were treated with TGFβ1 (10ng/mL) +/- Peptide 5 (25µM). A scrambled 
version was used as a control. 
 
Immunohistochemistry 
Immunohistochemical staining of paraffin-embedded sections (3µm-thick) of mouse renal 
cortex was performed as described previously.[41] After blocking, sections were incubated 
with antibodies for N-cadherin (NCAD) (ThermoFischer Scientific, PA5-17526, 1:100) and 
Zona Occludin-1 (ZO-1) (ThermoFischer Scientific, 61-7300, 1:100), and the Envision 
detection kit for 30mins at RT (DakoFrance, Trappes, France). Negative controls were 
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obtained by the removal of primary antibodies. The immuno-complex was visualised using 
DAB substrate and counterstained with hematoxylin. 
 
Total RNA Extraction and Quantitative Real-Time PCR 
Total RNA was extracted from renal cortex using TRIzol reagent (Euromedex) RNA quality 
was checked by control of optical density (OD) at 260 and 280 nm. cDNA was synthesized 
from 1 mg RNA using the Fermentas H Minus First-Strand cDNA Synthesis Kit according to 
the manufacturer’s instructions. Quantitative PCR experiments were performed as 
previously described.[24] Each sample was run in triplicate, and analysis of relative gene 
expression was done by using the 2−ΔΔCT method. Results are expressed in graphs as 
arbitrary units, which represent the ratio of the target gene to the internal control gene 
(HPRT). Sequences of primers used in our studies are listed in table 1. 
 
Western blotting 
Preparation of cytosolic protein from human proximal tubule cells, separation by SDS-gel 
electrophoresis and transfer onto Immobilon-Fl PVDF membranes have been described 
previously.[43] Membranes were blocked with Odyssey blocking buffer (LI-COR), then probed 
with specific polyclonal antibodies against E-cadherin (1:1000), N-cadherin (1:1000), -
catenin (1:2000), Claudin-2 (1:500) and ZO-1 (1:1000). Bands were visualized using an 
OdysseyFC and semi-quantified using ImageStudio (v5.2, LI-COR). Immunoblotting of 
protein obtained from mouse cortical tissue was performed as above using: E-cadherin 
(Santa Cruz Biotechnology, sc-7870, 1:500), -catenin (BD Transduction Laboratories, 
610154, 1:1000) and Claudin-2 (ThermoFisher Scientific, 32-5600, 1:1000). 
 
Transepithelial Electrical Resistance 
Human renal tubule cells were seeded (6x104 cells/ml) onto Transwell filters (12mm 
diameter, pore size 0.4μM; Corning, NY) and incubated with TGF-β1 (10ng/mL) +/- Peptide 
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5 (25µM) for 48h. Scrambled Peptide 5 (25µM) was used as a control. Transepithelial 
electrical resistance (TER) was calculated in ohms/cm2 (Ώ.cm2).  
 
Atomic Force Microscopy Force Spectroscopy 
Adhesion was characterised using single-cell force spectroscopy (SCFS), as described 
previously.[44-45] Tip-less Arrow TL1 cantilevers (Nanoworld AG, Switzerland) with a low 
spring constant were used (0.03N/m). Cantilevers were sterilized with UV (10mins), before 
being functionalised in poly-L-lysine (25μg/ml, 30mins, RT), and fibronectin (20μg/ml, 2h, 
37°C). A single cell was captured at the end of the cantilever with a set force (0.8-1nN) and 
contact time (8-10sec). After attachment, the cell was left to recover for >5min, allowing 
surface binding. The cantilever-attached cell was brought into contact with a substrate cell, 
until a 1nN contact force was reached. The two cells were attached for 10sec to allow cell-
cell adhesion, after which the cantilever was retracted at a constant speed (5μm/sec). Force-
displacement curves were measured until complete detachment (pulling length of 40-90μm). 
Each procedure occurred in triplicate with 45sec intervals.  
 
Carboxyfluorescein 
HK2 and hPTEC cells were incubated with TGF-β1 (10ng/mL) +/- Peptide 5 (25µM) or 
Scrambled (25M) for 48h. Cells were exposed to Ca2+-free Balance Salt Solution (BSS) + 
carboxyfluorescein (200µM) for 10min to permit hemichannel-mediated dye uptake, before 
reapplying [Ca2+]e to close the channels. Images were acquired with a Cool Snap HQ CCD 
camera (Roper Scientific) and Metamorph software (Universal Imaging Corp., Marlow, 
Bucks, UK). ImageJ was used to quantify dye uptake, where a region of interest was drawn 
around each cell (10-15cells/dish) and mean pixel intensity measured.  
 
ATP Biosensing 
ATP-biosensors (Sarissa Biomedical, Coventry UK) were used in simultaneous dual-
recording ampomeric mode as described previously.[11] A null sensor accounted for non-
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specific electro-active artefacts and was subtracted from the ATP trace. Glycerol (2mM) was 
included in all solutions. HK2 cells were incubated with TGF-β1 (10ng/mL) +/- Peptide 5 
(25µM) for 48h. Cells were transferred to a chamber containing Ca2+-containing BSS 
perfused at 6ml/min (37°C) and left for 10min to acclimatize. Ca2+-free BSS was used to 
open hemichannels and Ca2+-containing BSS to close them. Data was calibrated using 
10M ATP. Recordings were acquired at 4Hz with a Micro CED (Mark2) interface using 
Spike software. 
 
Analysis 
Statistical analysis was performed via one-way ANOVA test with Tukey’s multiple 
comparison post-test or t-test. Data are expressed as mean±SEM, with ‘n’ denoting sample 
number. A p-value <0.05 denotes statistical significance. 
 
Results  
 
TGF-β1 regulates expression of adherens and tight junction proteins. 
Human Kidney proximal tubule epithelial cells were treated with TGF-β1 (2-10ng/mL) for 
48h. TGF-β1 downregulated E-cadherin to 39.7±5.5%, 37.3±6.2% and 38.5±4.1% as 
compared to control, and upregulated N-cadherin to 170.5±24.7%, 194.2±15% and 
213.3±28% at 2, 4 and 10ng/mL TGF-β1 respectively (Figure 1A&B). TGF-β1 did not alter β-
catenin expression (Figure 1C). Expression of the tight junction protein Claudin-2, was 
reduced to 62.3±12.2%, 61.6±4.5% and 60.5±4.4% of control at 2, 4 and 10ng/mL TGF-β1 
(Figure 1D), whilst ZO-1 decreased to 67.0±8%, 69.2±1.7% and 64.8±4.1% respectively 
(Figure 1E). 
 
ATPγS regulates adherens and tight junction proteins. 
We previously demonstrated that TGF-β1 increased hemichannel-mediated ATP release [11]. 
To determine if ATP mediates changes in adherens and tight junction protein expression, 
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human kidney proximal tubule cells were incubated with ATPγS (1-100µM) for 48h. The non-
hydrolysable P2-agonist decreased ECAD expression to 87.8±0.9%, 63.8±1.9% and 
43.4±6.1% as compared to control at 1, 10 and 100µM ATPγS, and increased NCAD 
expression to 136.2±7.6%, 158.4±7.3% and 181.3±6.3% respectively (Figure 2A&B). No 
change in β-catenin expression was observed (Figure 2C). ATPγS decreased Claudin-2 to 
72.7±9.8%, 61.6±11.6% and 42±2.6% of control (Figure 2D) and ZO-1 to 83.7±11.4%, 
73±1.8% and 45.9±1.4% (Figure 2E) at 1, 10 and 100µM respectively.  
 
ATP is downstream of TGF-β1 in regulating expression of adherens junction proteins. 
To delineate a downstream role for ATP, human proximal renal tubule cells were incubated 
with TGF-β1 (10ng/mL) ± apyrase (5U/ml) for 48h. As expected, TGF-β1 (10ng/mL) 
decreased ECAD expression to 20.9±1.4%, whilst co-incubation with apyrase partially 
restored expression (51.2±3.2%, Figure 3A). Apyrase reduced the TGF-1 evoked increase 
in NCAD from 191.1±12.6% to 133.3±9.1%, as compared to control (Figure 3B). TGF-β1 
failed to significantly change β-catenin expression (Figure 3C).  
 
Our previous work confirmed that TGF-1 reduces E-cadherin mediated adhesion in human 
renal tubule cells.[11] On this basis, we assessed the effect of ATP on cell-to-cell tethering. A 
single cell (±100μM ATPγS, 48h) was attached to a tip-less cantilever (probe cell) and 
brought into contact with a substrate cell (Figure 3D). The two cells were attached with fixed 
force (1nN) and contact time (10sec) after which the probe cell was retracted. Force versus 
displacement was recorded continuously. The zero axis represents the baseline in which the 
two cells were completely detached, whilst the lowest negative point below the baseline 
represents maximum unbinding force (Fmax). Analysis determined a reduction in the mean 
unbinding forces between cells treated with ATPγS (Figure 3D&F) from 1.836nN +/- 0.055 to 
1.279nN +/- 0.064. Furthermore, a reduction in force variability occurs (Figure 3E). 
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Apyrase failed to negate TGF-β1-evoked changes in tight junction protein expression. As 
expected, TGF-β1 (10ng/mL) reduced expression of Claudin-2 (Figure 3G) and ZO-1 (Figure 
3H) to 48.6±11.3% and 9.5±4% respectively, compared to the control. Co-incubation with 
apyrase failed to negate this reduction, with expression remaining at 33.3±4.9% and 
9.5±3.5% for Claudin-2 and ZO-1 respectively. Trans-epithelial electrical resistance (TER) 
confirmed loss of tight junction function in cells cultured with TGF-β1 (10ng/mL) or ATPγS 
(100µM) for 48h. TER confirmed that TGF-β1 and ATPγS decreased epithelial resistance 
from 67.7±5.5Ω.cm2 to 27.6±2 Ω.cm2 and 42.6±3 Ω.cm2 respectively (Fig 3I). 
 
Purinoreceptor, P2X7, exhibits increased expression in our in vitro and in vivo models 
of disease.  
Immunohistochemistry of purinoreceptor isoforms P2Y2, P2Y6 and P2X7 (Figure 4) in 
biopsy material isolated from people with and without DN confirmed upregulation of P2Y2 
(Fig 4A&B) (IOD: 63120±9485 versus 39400±142 for control, Figure 4C&D), with a decrease 
in P2Y6 (Fig 4F&G) (IOD: 54850±2337 versus 73170±574 for control, Figure 4H&I). P2X7 
expression was significantly increased (Fig 4K&L) (IOD: 16130±2715 compared to 4013±62, 
for control; Figure 4M&N). 
 
To confirm if TGF-β1 regulates purinoreceptor expression in vitro, cells were incubated with 
TGF-β1 (2-10ng/mL) for 48h. TGF-β1 failed to significantly change P2Y2 expression (Figure 
4P) yet a significant down-regulation of P2Y6 to 54.1±8.8%, 49.8±2.8% and 36.6±2.5% at 2, 
4 and 10 ng/mL TGF-β1 respectively was observed (Figure 4Q). In contrast, a significant 
increase in P2X7 was observed at 2, 4 and 10ng/mL TGF-β1 (206.4±18.7%, 313.3±29.9% 
and 389.1±6.2% respectively, Figure 4R). 
 
Lastly, quantitative PCR experiments confirmed that purinergic receptor expression in 
tubules isolated from the UUO mouse model exhibit a similar pattern of expression to that 
observed in human biopsy material and in our TGF-1 treated cells. qRT-PCR of 
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purinoreceptor isoforms P2Y2, P2Y6 and P2X7 (Figure 4S-U) confirmed upregulation of 
P2Y2 (Fig 4S) (0.68±0.16 to 1.1+/-0.11), with a decrease in P2Y6 (Fig 4T) (15.0±0.86 to 
7.2±0.97) and a significant increase in  P2X7 (Fig4U) expression (1.3±0.15 to 6.3±0.25) as 
compared to WT control.   
 
Blocking P2X7 negates TGF-β1-evoked changes in adherens & tight junction proteins. 
Purinergic receptor P2X7, has been linked to fibrosis in multiple disease states.[37-40] Given 
the statistically significant increase in P2X7 expression in both human biopsy material and in 
our UUO mouse, the pathophysiological role of P2X7 in mediating the downstream effects of 
ATP induced tubular injury in our model system were investigated.  
 
To determine if TGF-1 evoked changes in hemichannel mediated ATP release, facilitates 
its effects via activation of P2X7, HK2 cells were treated with TGF-β1 ± Suramin (100µM) or 
P2X7-specific inhibitors A438079 (50µM) or A804598 (50nM). The TGF-β1-evoked loss in 
ECAD expression (Figure 5A), was partly restored, from 22.2±5.5% to 83.1±5% (Suramin), 
52.8±5.4% (A438079) and 44.4±4% (A804598), whilst NCAD expression (Figure 5B) 
decreased from 374±16.3% to 141.8±14.4% (Suramin), 202.5±15% (A438079) and 
192.5±32.6% (A804598). No change in β-catenin was observed (Figure 5C). 
 
Inhibition of P2X7 partially reversed loss of tight junction protein expression evoked by TGF-
β1. Claudin-2 (Figure 5D) levels were restored from 33.4±1% to 91.5±13.4% (Suramin), 
52.6±2.1% (A438079) and 60.7±2.8% (A804598) and ZO-1 (Figure 5E) returned from 
54.5±5.2% to 88.3±9.3% (Suramin), 112.8±6.3% (A438079) and 106.4±10.1% (A804598). 
For all experiments, inhibitors alone failed to induce any significant change in expression. 
 
Peptide 5 inhibits TGF-β1-induced Cx43 hemichannel activity and ATP release. 
To study the efficacy of Peptide 5 in blocking Cx43 mediated hemichannel activity in renal 
tubule epithelial cells, HK2 and hPTECs were incubated in TGF-β1 (10ng/mL) ± Peptide 5 
 15 
(25µM) for 48h. Dye uptake increased in TGF-β1-treated HK2 cells to 609.4±46% compared 
to unstimulated control (Figure 6A&B), whilst co-incubation with Peptide 5 reduced uptake to 
163±10.2%. Co-incubation with scrambled peptide failed to blunt the TGF-1 response 
(671.5±29.5%, Figure 6A&B). The effects were matched in primary hPTECS, where Peptide 
5 significantly reduced uptake to 141.7±16.3% from 311.2±39.6% in TGF-1 treated cells 
(Figure 6C&D). Scrambled control failed to reverse the TGF-1 effects (323.3±58.1%). 
 
Biosensing uses enzymatically-coated electrodes to measure real time ATP release. 
Cultured as above, ATP release increased from 0.43±0.03µM to 6.10±0.36µM in TGF-β1-
treated cells (Figure 6E&F). Peptide 5 successfully prevented ATP release, restoring levels 
to 0.60±0.20µM. Scrambled peptide in the presence of TGF-1 had no affect (5.45±0.53µM, 
Figure 6E&F). 
 
Peptide 5 negates TGF-β1 induced disassembly of the adherens and tight junction 
complex in human primary renal tubule cells  
Having confirmed the efficacy of Peptide 5, a role for TGF-1 induced Cx43 mediated 
hemichannel ATP release in initiating early changes of tubular injury were assessed. Human 
renal proximal tubule epithelial cells were incubated with TGF-β1 (10ng/mL) ± Peptide 5 
(25µM) for 48h. Co-incubation of hPTECs with TGF-1 and Peptide 5 restored ECAD 
expression (Figure 7A) from 31.5±9.2% to 108.9±17.1%; NCAD expression (Figure 7B) from 
280.5±16.7% to 154.7±10.6%; Claudin-2 expression (Figure 7C) 65.3±5.4% to 100.9±10% 
and finally ZO-1 expression (Figure 7C) from 59.63±3.1% to 91.6±12.8% as compared to 
low-glucose control. Incubation of cells with either Peptide 5 alone or a scrambled version of 
Peptide 5, failed to change expression of our candidate proteins.  
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Regulation of junctional components in UUO mice is Cx43-dependent. 
Having confirmed a role for Cx43 mediated ATP release in TGF-1 induced tubular injury 
pharmacologically, the expression of key candidate proteins was assessed in vivo using our 
Cx43+/- mouse model of UUO. Quantification of immunohistochemistry determined an 
increase in N-cadherin from 0.131±0.02% to 1.59±0.19% (Figure 8A&C) and a decrease in 
ZO-1 from 2.38±0.43% to 0.293±0.02% (Figure 8B&D) in UUO mice compared to WT 
healthy animals. Genetic depletion of Cx43 partially negated these changes, returning 
expression to 0.734±0.13% (Figure 8A) and 0.402±0.04% (Figure 8B) for N-cadherin and 
ZO-1 respectively. Staining in Cx43+/- sham animals was unaltered from WT sham controls 
for both proteins. 
 
In accordance with previous data, expression of E-cadherin was downregulated from 
115.79±14.34% to 66.61±4.91% (Figure 8E&F); -catenin upregulated from 126.04±18.38% 
to 880.42±16.76% (Figure 8E&G) and Claudin-2 downregulated from 107.15±3.68% to 
100.61±8.63% (Figure 8E&H), in WT UUO mice as compared to WT shams. In Cx43+/- UUO 
mice, expression of E-cadherin was restored to 98.73±10.25% (Figure 8E&F) and -catenin 
to 376.43±18.56% (Figure 8E&G). Claudin-2 exhibited minimal change at 109.08±20.23% 
(Figure 8E&H).  
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Discussion 
Tubulointerstitial fibrosis is the final common pathway in CKD, yet treatment represents an 
unmet clinical need. The emerging field of connexins suggests that these membrane bound 
proteins may offer a viable therapeutic target in future treatment of disease,[46] with recent 
studies confirming that increased expression of Cx43 in the proximal region of the diabetic 
kidney, is accompanied by loss of gap junction mediated intercellular communication and 
increased hemichannel mediated ATP release.[11] Elevated levels of ATP have been linked 
to inflammation and fibrosis in multiple disease states [28-31]. And work within our laboratory 
confirms increased expression of inflammatory and profibrotic markers in ATP treated 
human primary proximal tubule cells. [11] In the current study we investigate a role for 
aberrant Cx43 mediated hemichannel activity in mediating the phenotypic and functional 
changes of early tubular injury,[11] .  
 
As the key underlying pathology of End Stage Renal Disease, tubulointerstitial fibrosis is 
partly contributed to, by Epithelial to Mesenchymal Transition (EMT).[32] EMT occurs in the 
face of injury as cells attempt to evade apoptosis. In doing so, cells downregulate markers 
commonly associated with an epithelial phenotype, e.g. E-cadherin, ZO-1, and Claudin-2 
whilst upregulating those more commonly associated with a mesenchymal phenotype and 
increased fibrosis, e.g. -SMA, N-cadherin, and Snail.[32-34] Initiation is associated with 
disassembly and breakdown of adherens junctions and tight junctions, culminating in loss of 
cell adhesion and increased paracellular permeability.  
 
Previous findings from our lab, confirm that TGF-1 mediates morphological and phenotypic 
changes characteristic of EMT in both HK2 and hPTECs.[11][27] Furthermore, TGF-1 evokes 
an increase in Cx43 expression, an effect dependent upon SMAD2/SMAD3 signalling,[11] 
and corroborated by multiple studies confirming direct binding of Smad3 and Smad4, to the 
promoter of Gja1. [47-48] As previously reported in podocytes, it is plausible that TGF-1 may, 
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via crosstalk with the STAT1 signalling pathway[21]  mediate Cx43 hemichannel expression 
via AKT/p38 signaling and the binding of STAT1/c-Jun to the Cx43 promoter.[21] In the 
current study; we present novel evidence that TGF-1 evokes increased Cx43 hemichannel-
mediated ATP release, which in turn, contributes to purinergic mediated disassembly of tight 
junctions and adherens junctions in the proximal region of the diseased kidney.  
 
Our In vitro studies confirm that incubation of renal proximal tubule cells with TGF-β1, or 
non-hydrolysable ATPγS decreased expression of E-cadherin, Claudin-2 and ZO-1, with 
increased expression of N-cadherin. To delineate the functional consequences of these 
altered levels of expression, atomic force microscopy force spectroscopy and trans-epithelial 
electrical resistance assessed changes in cell-cell tethering and paracellular permeability 
respectively. Corroborating recent findings that depletion of Claudin-2 and ZO-1 is 
detrimental to proximal tubule epithelial cell function through a “leaky” epithelia, [49] both 
TGF-β1 and ATPγS independently reduce PTEC resistance, and ultimately impair barrier 
integrity. Furthermore, force spectroscopy confirmed ATPγS reduced the unbinding force 
required to uncouple two attached cells. Co-incubation of TGF-β1 with the ectonucleotidase 
apyrase, partially restored expression of E-cadherin and N-cadherin, yet failed to negate 
TGF-1 evoked changes in tight junction protein expression. These observations, can most 
likely be explained by studies confirming a role for ATP metabolites in regulating expression 
of tight junction proteins, [50-51] and are further supported by observations that TGF-1 
evoked changes in tight junction expression are blunted when cells are co-incubated with 
adenosine receptor antagonist; Suramin. The origin of this deleterious signal was confirmed 
in TGF-1 treated cells preincubated with Peptide 5.  Peptide 5 is a 12 amino acid peptide 
which targets the 2nd extracellular loop of Cx43,[52], It has been proven successful in blocking 
Cx43 hemichannels when delivered topically, intraocularly [53], into cerbebrospinal fluid and 
systemically [52]. Multiple approaches have been used to confirm target applicability and 
specificity and all have yielded similar and significant benefits across different injury models. 
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The ability of Peptide 5 to block hemichannel activity, ATP-release and ultimately 
disassembly of the adherens/tight junction complex in our model system, was assessed by 
carboxyfluorescein dye uptake, ATP-biosensing and western blotting respectively. Co-
incubation of both HK2 and hPTECS with TGF-1 and Peptide 5 significantly reduced dye 
uptake and restored ATP release to near basal, whilst Peptide 5 successfully prevented 
TGF-β1-evoked changes in expression of E-cadherin, N-cadherin, Claudin-2 and ZO-1 in 
human primary renal proximal tubule cells.  
 
Confirmation for Cx43 mediated ATP release in initiating these changes of early tubular 
injury, was confirmed in a Cx43+/- heterogeneous knockout mouse model having undergone 
unilateral ureteral obstruction (UUO). The UUO model recapitulates the fundamental 
pathogenic mechanisms that typify all forms of CKD including diabetic nephropathy and is 
widely used for the study of renal fibrosis and inflammation.[36] Staining renal cortex slices 
from wildtype UUO mice confirmed a decrease in N-cadherin and ZO-1 expression, whilst 
immunoblotting of isolated renal cortex protein demonstrated reduced E-cadherin 
expression, with increased expression of -catenin. Restoration of expression of the 
adherens junction proteins in the Cx43+/- UUO model supports our earlier findings where 
Cx43 block diminished hemichannel mediated ATP release. However, whilst changes in 
expression of our adherens junction proteins were recapitulated in vivo, minimal change was 
observed for tight junction protein Claudin-2. Despite this, ZO-1 expression was decreased 
in vitro and in vivo, an effect restored when hPTEC cells were co-incubated with Peptide 5, 
or Cx43 activity was suppressed (Cx43+/-). The importance of this to tubular function and 
subsequent injury, is supported by observations, which suggest that ZO-1 is a critical 
regulator of tight junction assembly,[54-55] with loss of expression linked to defects in tight 
junction assembly and a severely disrupted paracellular barrier.[54-56] Although not present in 
the mature adherens junction complex, tight junction biogenesis is characterized by an 
interaction between ZO-1 and cadherins, an association which allows for fusion of belt-like 
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tight junctions and gap junction formation.[57] In addition, in its capacity as a scaffolding 
protein, ZO-1 directly facilitates Cx43 mediated gap junction formation.[58] Thus, restoration 
of ZO-1 expression, through blockade of Cx43 hemichannel mediated ATP release, has 
potential to not just restore barrier function, but to maintain cell-to-cell adhesion through 
efficient adherens junction formation, blockade of EMT and restoration of direct GJIC.   
 
With an imbalance in ATP signalling &/or degradation linked to the underlying pathology of 
multiple diseases,[59-61] we investigated a role for downstream purinergic signalling in driving 
these Cx43 hemichannel mediated events. ATP signals via activation of membrane-bound 
purinoreceptors.[62] Increased activation of purinergic receptors, notably P2X7, has been 
linked to inflammatory damage in the renal vasculature, glomerulus and tubular regions in 
multiple experimental models of kidney disease.[62-64] In diabetic nephropathy, P2X7 
expression is associated with mesangial expansion and impaired glomerular filtration,[38] 
whilst genetic and pharmacological (AZ11657312) ablation of P2X7 in a mouse model of 
Type I diabetes impaired glomerular macrophage infiltration and decreased collagen IV 
deposition.[38] In  human biopsy material from people with diabetic nephropathy and in 
tubules isolated from the UUO mouse model, we observed a significant upregulation of 
P2X7 expression, an effect which was blunted when Cx43 expression was genetically 
reduced (Cx43+/-/UUO). Peptide 5, has been shown to negate inflammation and associated 
tissue damage in multiple systems of disease, specifically those where initial pathology 
appears perpetuated by activation of the nucleotide-binding domain and leucine-rich repeat 
containing (NLR) protein-3 (NLRP3) inflammasome.[65] Upregulated in classic immune cells 
(e.g. infiltrating macrophages) and tubular epithelial cells of the kidney, the NLRP3 
inflammasome is a protein complex involved in initiating the innate immune response [66], 
with activation linked to a variety of glomerular and tubulointerstitial diseases.[67] Although 
pharmacological inhibition negates inflammation and improves overall tissue function in a 
host of inflammatory conditions, lack of understanding of structure and underlying regulatory 
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mechanisms of NLRP3 has hindered the discovery and development of successful 
therapeutics.[66] 
 
Stimulated by age-related Damage-associated molecular patterns (DAMPs), including 
excess ATP, P2X7 mediated activation of the NLRP3 complex triggers a cascade of events 
that culminate in secretion of downstream pro-inflammatory mediators, including interleukin-
1β (IL-1β) and interleukin-18 (IL-18).[66] A recent study in acute renal injury confirmed that 
the Cx43+/- mouse exhibits reduced renal NLRP3 expression and decreased serum levels of 
IL1 as compared to its wildtype control. [68] Moreover, NLRP3 activation has recently been 
linked to induction of EMTand diminished ECAD expression in multiple cell types,[69-70] whilst 
Cx43 mediated NLRP3 activation initiates breakdown and disruption of the retinal pigment 
epithelium (RPE) at the back of the diabetic eye.[65] In addition, with priming of the NLRP3 
inflammasome linked to nuclear factor-kappa B (NF-kB) activation, combined with reports 
that nuclear factor-kappa B (NF-kB) activation binding to the Cx43 gene promoter directly 
increases Cx43 expression[72], it is possible that inflammasome pathway priming parallels 
increased Cx43 expression, further perpetuating aberrant Cx43 mediated ATP release [65] . 
The current study confirms that specific inhibition of P2X7 in PTECS co-incubated with TGF-
1 +/- P2X7 inhibitor A438079 or A804598, negates TGF-β1-evoked changes in expression 
of EMT markers, E-cadherin, N-cadherin, Claudin-2 and ZO-1. In addition, using AFM-
SCFM, we have recently shown that the ATPγS induced downregulation of E-cadherin 
expression in proximal kidney cells, is paralleled by a P2X7 mediated reduction in 
intercellular ligation forces, decreased tether rupture events and cytoskeletal remodeling[73]. 
Combined with observations that Peptide 5 negates TGF-1 induced disassembly of the 
adherens junction and tight junction complex, our findings suggests that TGF-1 evoked 
changes in Cx43 mediated ATP likely initiates P2X7 mediated tubular injury and EMT via an 
NLRP3 dependent mechanism.  
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However, although blockade of P2X7 and an impaired ATP driven response clearly supports 
a role for purinergic mediated signalling in early tubular injury, recent clinical trials have 
failed to demonstrate a beneficial effect of P2X7 antagonism in numerous inflammatory 
illnesses, an effect most likely linked to the genetic variation within the P2X7.[74] With 
aberrant Cx43 activity linked to activation of P2X7 and NLRP3, targeting aberrant Cx43 
mediated hemichannel ATP release clearly represents a future therapeutic avenue for the 
treatment of chronic kidney disease and other conditions where inflammation appears to be 
the underlying pathology.  
 
Conclusions 
Our study is the first to provide insight into the initiating trigger of early phenotypic changes, 
which predispose cells of the injured proximal tubule to tubular injury. Elevated levels of 
TGF-1 increase Cx43 hemichannel mediated ATP release, an effect which drives P2X7 
mediated phenotypic changes linked to initiation of EMT in the tubular region of the kidney. 
With previous work in the Cx43+/- UUO model linking reduced Cx43 expression to diminished 
levels of extracellular matrix deposition, fibroblast activation and macrophage infiltration [24], 
the current study utilises Peptide 5 and confirms that the protective effects as observed in 
the Cx43+/- UUO mouse, appear to stem from inhibition of aberrant Cx43 mediated 
hemichannel ATP release. In conclusion, Cx43 represents, a viable therapeutic intervention 
for tubular damage in late stage CKD via restoration of the phenotypic and functional 
changes that culminate in an inflammatory and fibrotic phenotype. 
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Figure Legends:  
Figure 1: TGF-β1 regulates the expression of adherens and tight junction proteins in 
cultured human renal tubule cells. Cells were cultured in low glucose control (0) ±TGF-β1 (2-
10ng/mL) for 48h. Whole-cell expression of E-cadherin (Figure 1A), N-cadherin (Figure 1B), 
β-catenin (Figure 1C), Claudin-2 (Figure 1D), and ZO-1 (Figure 1E) was confirmed via 
immunoblotting. Representative blots for each protein are shown, with expression 
normalized by re-probing for ɑ-tubulin as a loading control. Bars correspond to their 
associated lanes in the respective blot. Results were from three or more separate 
experiments; with key significance shown: **P<0.01; ***P<0.001.  
 
Figure 2: ATPγS regulates the expression of major adherens and tight junction proteins in 
cultured human renal tubule cells. Cells were cultured in low glucose control (0) ±ATPγS (1-
100µM) for 48h. Whole-cell expression of E-cadherin (Figure 2A), N-cadherin (Figure 2B), β-
catenin (Figure 2C), Claudin-2 (Figure 2D) and ZO-1 (Figure 2E) were assessed through 
immunoblotting. Representative blots for each protein are shown, with expression 
normalized by re-probing for ɑ-tubulin as a loading control. Bars correspond to their 
associated lanes in the respective blot. Results were from three or more separate 
experiments; with key significance shown: *P<0.05; **P<0.01; ***P<0.001.  
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Figure 3: The ATP-diphosphohydrolase, apyrase negates TGF-β1-evoked changes in 
expression of the adherens junction complex, but fails to restore TGF-1 induced changes in 
tight junction protein expression. To determine whether ATP mediates TGFβ1-evoked 
changes in the expression of adherens and tight junction proteins, cells were cultured in low 
glucose (cont) ± TGF-β1 (10ng/mL) ± apyrase (5U/ml) for 48h. Whole-cell expression of E-
cadherin (Figure 3A), N-cadherin (Figure 3B), β-catenin (Figure 3C), Claudin-2 (Figure 3G), 
and ZO-1 (Figure 3H) were assessed via immunoblotting. Representative blots for each 
protein are shown, with expression normalized by re-probing for ɑ-tubulin as a loading 
control. Bars correspond to their associated lanes in the respective blot. Changes in 
expression were matched to changes in function (Figure 3D-F) and (Figure 3I). Atomic Force 
Microscopy single-cell force spectroscopy was used to measure the maximum unbinding 
force required to uncouple two adhered cells. Human renal tubule cells were cultured in low 
glucose with/without ATPγS (100µM) for 48h. Retraction Force-displacement curves for 
control and ATPγS (Figure 3D) cells are shown respectively. Maximum unbinding forces 
(Figure 3E&F) between two cells was determined by measuring the amplitude of the points 
circled in red (Figure 3D). Lastly, disassembly of the tight junction complex is paralleled by 
loss of transepithelial electrical resistance (TER). Cells were cultured in low glucose ± either 
TGF-β1 (10ng/mL) or ATPγS (100µM) for 48h on Transwell inserts. Data is expressed as 
mean ± SEM of multiple cells from 4 separate experiments, with key significance shown: 
**P<0.01, ***P<0.001.  
 
Figure 4: P2X7 is upregulated in renal tubule cells exposed to TGF-1 and in patients with 
CKD and in the UUO mouse mdoel. Staining of biopsy material isolated from individuals with 
DN was performed for P2Y2 (Fig4A&B), P2Y6 (Fig4F&G), and P2X7 (Fig4K&L). Staining for 
non-diabetic controls can be observed in P2Y2 (Fig4C&D), P2Y6 (Fig4H&I), and P2X7 
(Fig4M&N). Magnification: 400X. hPTECs were also cultured in low glucose with/without 
TGF-β1 (2-10ng/mL) for 48h. Whole-cell abundance of P2Y2 (Figure 4P), P2Y6 (Figure 4Q) 
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and P2X7 (Figure 4R) were determined through densitometry. Representative blots for each 
protein are shown, with expression normalized by re-probing for ɑ-tubulin as a loading 
control. Bars correspond to their associated lanes in the respective blot. qRT-PCR was 
performed on tubules isolated from WT (UUO) and Cx43 +/- (UUO) for P2Y2 (Fig4S), P2Y6 
(Fig4T) and P2X7 (P2Y7). qRT-PCR are expressed in graphs as arbitrary units (a.u.) that 
represent the ratio of the target gene to internal control gene (HPRT). Results were from 
three or more separate experiments; with key significance shown: *P<0.05; ***P<0.001.  
 
Figure 5: Blockade of purinoreceptors attenuates TGF-β1 induced changes in expression of 
adherens and tight junction protein. HK2 cells were cultured in low glucose ± TGF-β1 
(10ng/mL) ± either: Suramin (100µM), A438079 (50µM) or A804598 (50nM) for 48h. Whole-
cell expression of E-cadherin (Figure 5A), N-cadherin (Figure 5B), β-catenin (Figure 5C), 
Claudin-2 (Figure 5D) and ZO-1 (Figure 5E) were assessed via immunoblotting. 
Representative blots for each protein are shown, with expression normalized by re-probing 
for ɑ-tubulin as a loading control. Bars correspond to their associated lanes in the respective 
blot. Results were from three or more separate experiments; with key significance shown: 
*P<0.05; **P<0.01; ***P<0.001.  
 
Figure 6: Co-incubation of TGF-1 treated renal tubule cells with Cx43 mimetic, Peptide 5, 
impairs hemichannel activity and ATP release. HK2 cells and hPTECs were cultured on 
either fluorodishes or glass coverslips in low-glucose (cont) ± TGF-β1 (10ng/mL) ± Peptide 5 
(25μM) for 48h. A carboxyfluorescein uptake assay (Figure 6A&C) assessed hemi-channel 
activity in HK2 and hPTEC cells respectively. Minimal dye uptake was observed in control 
cells, whilst strong dye loading occurred in TGF-β1 treated cells. Co-incubation with Peptide 
5 attenuated dye loading, whilst a scrambled control had no significant effect. Pixel intensity 
of dye loading was quantified and compared to the low-glucose control (Figure 6B&D) for 10 
cells in 3 separate experiments. Biosensors were used to measure hemi-channel dependent 
release of ATP. Representative traces (-null) are shown (Figure 6E). The amplitude of any 
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major ATP peak was measured and compared to control recordings, where little response 
occurred in response to hemi-channel opening following the removal of calcium. TGF-β1-
treated cells exhibit significant ATP in response to hemi-channel opening, an effect negated 
when co-incubated with Peptide 5 (25µM) (Figure 6F). Exogenous ATP was administered at 
the end of each experiment ensuring effective calibration. Data is expressed as mean ± 
SEM of multiple cells from 4 separate experiments, with key significances shown: **P<0.01, 
***P<0.001.  
 
Figure 7: Blockade of Cx43-mediated hemichannel ATP release, negates the TGF-β1-
induced disassembly of the tight and adherens junction complex. hPTECs were cultured in 
low glucose (cont) ±TGF-β1 (10ng/mL) ± Peptide 5 (25µM) for 48h. Expression of E-
cadherin (Figure 7A), N-cadherin (Figure 7B), Claudin-2 (Figur 7C) and ZO-1 (Figure 7D) 
were assessed via western blotting. Representative blots for each protein are shown, with 
expression normalized by re-probing for ɑ-tubulin as a loading control. Bars correspond to 
their associated lanes in the respective blot. Results were from three or more separate 
experiments; with significance shown: *P<0.05; **P<0.01.  
 
Figure 8: Cx43+/- mice exhibit minimal disassembly of the adherens and tight junction 
complex. Quantification of immunohistochemical staining determined an increase in N-
cadherin (Figure 8A) and decrease in ZO-1 (Figure 8B) expression in wildtype (WT) UUO 
compared to WT sham controls. In Cx43+/- (UUO) mice, expression of both markers was 
partially restored to near basal levels. Furthermore, Western blotting of renal cortex 
determined changes in expression of E-cadherin (Figure 8C), -catenin (Figure 8D) and 
Claudin-2 (Figure 8E) in WT UUO mice compared to WT shams, congruent to those found in 
vitro when cells were treated with TGF-1. As expected, these changes were partially 
negated in Cx43+/- (UUO) mice. Results were from six separate experiments; with 
significance shown: *P<0.05; **P<0.01; ***P<0.001.  
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Table 1 
Gene Sequence 
P2Y2 FW: TCAAACCGGCTTATGGGACC 
RV: GGCAGCTGAGGTCAAGTGAT 
P2Y6 FW: GGGTAGTGTGTGGAGTCGTG 
RV: AGCGAGTAGACAGGATGGGT 
P2X7 FW: GCACGAATTATGGCACCGTC 
RV: CCCCACCCTCTGTGACATTC 
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